EcoDrugPlus

Protein Kinase, Dna-Activated, Catalytic Subunit

Ensembl ID : ENSHCOG00000011499
Gene Symbol: PRKDC
3 Cross references
184 Possible Orthologues:

Protein Tyrosine Kinase 2

Ensembl ID : ENSHCOG00000015835
Gene Symbol: PTK2
3 Cross references
246 Possible Orthologues:

Protein Tyrosine Kinase 2 Beta

Ensembl ID : ENSHCOG00000007778
Gene Symbol: PTK2B
3 Cross references
195 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11

Ensembl ID : ENSHCOG00000004751
Gene Symbol: PTPN11
3 Cross references
251 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSHCOG00000009159
Gene Symbol: PTPRB
2 Cross references
203 Possible Orthologues:

Protein-Serine O-Palmitoleoyltransferase Porcupine-Like

Ensembl ID : ENSHCOG00000013323
Gene Symbol: LOC109528448
3 Cross references
197 Possible Orthologues:

Protein-Tyrosine Kinase 6-Like

Ensembl ID : ENSHCOG00000004425
Gene Symbol: LOC109528635
3 Cross references
159 Possible Orthologues:

Proteinase-Activated Receptor 1-Like

Ensembl ID : ENSHCOG00000011058
Gene Symbol: LOC109529262
3 Cross references
263 Possible Orthologues:

Proto-Oncogene Tyrosine-Protein Kinase Src

Ensembl ID : ENSHCOG00000008735
Gene Symbol: LOC109513573
3 Cross references
197 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSHCOG00000003853
Gene Symbol: P2RY1
3 Cross references
190 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSHCOG00000001257
Gene Symbol: P2RY4
2 Cross references
164 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSHCOG00000018971
Gene Symbol: P2RY4
3 Cross references
164 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).